Avenue Therapeutics, Inc.

NasdaqCM ATXI

Avenue Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Avenue Therapeutics, Inc. EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: ATXI

Avenue Therapeutics, Inc.

CEO	Dr. Alexandra MacLean M.D.
IPO Date	June 27, 2017
Location	United States
Headquarters	1140 Avenue of the America
Employees	3
Sector	Health Care
Industries Pharmaceuticals

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Key trends

Past 5 years